Actively Recruiting
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Led by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Updated on 2024-06-14
130
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.
CONDITIONS
Official Title
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Fully understand the study and voluntarily sign the informed consent form.
- Male or female 18-70 years of age.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0.
- Life expectancy ≥ 3 months.
You will not qualify if you...
- Patients deemed unsuitable for participating in the study by the investigator for any reason.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Army Medical University
Chongqing, Chongqing Municipality, China
Actively Recruiting
Research Team
C
Cheng Wei
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here